Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

被引：27

作者：

Nooka, Ajay K. ^{[1
]}

Weisel, Katja ^{[2
]}

van de Donk, Niels W. C. J. ^{[3
]}

Routledge, David ^{[4
,5
]}

Otero, Paula Rodriguez ^{[6
]}

Song, Kevin ^{[7
]}

Quach, Hang ^{[8
]}

Callander, Natalie ^{[9
]}

Minnema, Monique C. ^{[10
]}

Trudel, Suzanne ^{[11
]}

Jackson, Nicola A. ^{[12
]}

Ahlers, Christoph M. ^{[13
]}

Im, Ellie ^{[14
]}

Cheng, Shinta ^{[15
]}

Smith, L. ^{[15
]}

Hareth, Nahi ^{[16
]}

Ferron-Brady, Geraldine ^{[13
]}

Brouch, Maria ^{[13
]}

de Oca, Rocio Montes ^{[13
]}

Paul, Sofia ^{[13
]}

Holkova, Beata ^{[13
]}

Gupta, Ira ^{[13
]}

Kremer, Brandon E. ^{[14
]}

Richardson, Paul ^{[17
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[2] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, D-20246 Hamburg, Germany

[3] Vrije Univ Amsterdam, Amsterdam UMC, Canc Ctr Amsterdam, Dept Hematol, NL-1081 HV Amsterdam, Netherlands

[4] Peter MacCallum Canc Ctr, Melbourne, Vic 3000, Australia

[5] Royal Melbourne Hosp, Melbourne, Vic 3000, Australia

[6] Clin Univ Navarra Pamplona, Ctr Invest Med Aplicada, Navarra 31008, Spain

[7] Vancouver Gen Hosp, Vancouver, BC V5Z 1M9, Canada

[8] Univ Melbourne, St Vincents Hosp Melbourne, Dept Haematol, Melbourne, Vic 3065, Australia

[9] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53705 USA

[10] Univ Med Ctr Utrecht, Dept Hematol, NL-3584 CX Utrecht, Netherlands

[11] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Dept Med, Toronto, ON M5G 2C1, Canada

[12] GlaxoSmithKline, Stockley Pk, London, England

[13] GlaxoSmithKline, Upper Providence, PA 19426 USA

[14] GlaxoSmithKline, Waltham, MA 02451 USA

[15] SpringWorks Therapeut, Stamford, CT 06902 USA

[16] Karolinska Univ Hosp, Dept Med, SE-17176 Stockholm, Sweden

[17] Dana Farber Canc Inst, Dept Med Oncol, Div Hematol Malignancies, Boston, MA 02215 USA

来源：

FUTURE ONCOLOGY | 2021年 / 17卷 / 16期

关键词：

antibody-drug conjugate; BCMA; belantamab mafodotin; clinical trial; dostarlimab; feladilimab; GSK3174998; multiple myeloma; nirogacestat; platform study;

D O I：

10.2217/fon-2020-1269

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received >= 4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma.

引用

页码：1987 / 2003

页数：17

共 50 条

[41] Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in RealLife Setting: The ALFA Study
Roussel, Murielle
Texier, Nathalie
Germain, Raphael
Sapra, Sandhya
Paka, Prani
Kerbouche, Naima
Colin, Xavier
Leleu, Xavier
BLOOD, 2022, 140 : 4261 - 4263
[42] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience
Hultcrantz, Malin
Orozco, Jennifer
Peterson, Tim J.
Derkach, Andriy
Hassoun, Hani
Korde, Neha
Lu, Sydney X.
Mailankody, Sham
Patel, Dhwani
Shah, Urvi A.
Tan, Carlyn
Maclachlan, Kylee H.
Chung, David J.
Landau, Heather J.
Shah, Gunjan L.
Lahoud, Oscar B.
Scordo, Michael
Landgren, Ola
Giralt, Sergio
Lesokhin, Alexander
BLOOD, 2021, 138
[43] OUTCOMES OF IDECABTAGENE VICLEUCEL IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PREVIOUSLY TREATED WITH BELANTAMAB MAFODOTIN
Melody, Megan
Przybylski, Daniel
Robinson, Adam
Lin, Adam
Gordon, Leo
Adekola, Kehinde
Singhal, Seema
Mehta, Jayesh
Moreira, Jonathan
BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 210 - 211
[44] Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3
Hungria, Vania T. M.
Weisel, Katja
Radinoff, Atanas
Delimpasi, Sosana
Mikala, Gabor
Masszi, Tamas
Li, Jian
Capra, Marcelo
Maiolino, Angelo
Pappa, Vasiliki
Chraniuk, Dominik
Osipov, Iurii
Leleu, Xavier
Low, Michael
Matsumoto, Morio
Li, Mary
Sule, Neal
Polinkovsky, Margaret
Davis, Randy
Bright, Shelley
McKeown, Astrid
Opalinska, Joanna
Dimopoulos, Meletios Athanasios
BLOOD, 2023, 142
[45] Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)
Popat, Rakesh
Kazantzi, Aikaterini
Farooq, Asim
Thulasi, Praneetha
Lonial, Sagar
Jakubowiak, Andrzej
Badros, Ashraf Z.
Jeng, Bennie H.
Opalinska, Joanna
Baron, January
Piontek, Trisha
Byrne, Julie
Womersley, Lynsey
Gupta, Ira
Esposti, Simona Degli
BLOOD, 2020, 136
[46] Belantamab mafodotin concentration-QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM-1 and-2 studies
Jewell, Roxanne C.
Mills, Richard J.
Farrell, Colm
Visser, Sandra A. G.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (10) : 2571 - 2581
[47] Phase I/II Study of Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone (BelCyd) in Relapsed/Refractory Multiple Myeloma
Badros, Ashraf Z.
Nash, Thea
Lawrance, Christopher
Tittle, Brandon
Philip, Sunita
Sunshine, Sarah
Munir, Wuqaas
Fan, Xiaoxuan
Ide, Christina
Atanackovic, Djordje
BLOOD, 2023, 142
[48] Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma
Wahab, Ahsan
Rafae, Abdul
Mushtaq, Kamran
Masood, Adeel
Ehsan, Hamid
Khakwani, Maria
Khan, Aqsa
FRONTIERS IN ONCOLOGY, 2021, 11
[49] DREAMM-1 Patient perspectives from the first-in-human study of single-agent belantamab mafodotin for relapsed and refractory multiple myeloma (RRMM).
Eliason, Laurie
Opalinska, Joanna
Martin, Mona L.
Correll, Julia
Gutierrez, Benjamin
Popat, Rakesh
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[50] Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study
Hultcrantz, Malin
Kleinman, David
Vij, Ravi
Escalante, Fernando
Kotowsky, Nirali
Bitetti, Jacopo
Mackay, Christine
Boytsov, Natalie
Camadoo-O'Byrne, Leena
Germain, Guillaume
Duh, Mei Sheng
Laliberte, Francois
Mahendran, Malena
Urosevic, Ana
Lee, Hans C.
BLOOD, 2022, 140 : 10124 - 10126

← 1 2 3 4 5 →